ALVO (ALVO) Stock Price & Analysis
ALVO (ALVO) fell 3.77% to USD 3.06 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
ALVO last closed at USD 3.18; the session ranged USD 3.04–3.2 on volume of 577,585 shares. Market capitalization is $1.03B, with a 52-week range of USD 2.94–9.94 (NGM). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 3.06 |
|---|---|
| Change | ▼ 3.77% (down) |
| Previous Close | USD 3.18 |
| Open | USD 3.14 |
| Day Range | USD 3.04 – 3.2 |
| 52-Week Range | USD 2.94 – 9.94 |
| Volume | 577,585 shares |
| Market Cap | $1.03B |
| Exchange | NGM |
Technical Analysis (ALVO)
Nexqual's technical model rates ALVO "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.54 (neutral) |
| vs SMA50 | Below (USD 3.54) |
| MACD | -0.11 (negative) |
Analyst Ratings (ALVO)
Wall Street analysts rate ALVO "Buy" based on 5 analysts, with a mean price target of USD 6.5 (range USD 4–9.5), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 6.5 |
| High Target | USD 9.5 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 3 / 1 / 1 |
Earnings (ALVO)
| Next Earnings Date | 2026-08-19 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $124.01M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD 0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.03 ▼ miss |
| 2025-06-30 | USD 0.03 vs est -0 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (ALVO)
| Total Revenue | $562.04M |
|---|---|
| Revenue Growth (YoY) | -20.20% |
| Gross Margin | +61.53% |
| Operating Margin | +9.13% |
| Profit Margin | -14.36% |
| Current Ratio | 1.76 |
| Total Cash | $63.83M |
| Total Debt | $1.46B |
| Free Cash Flow | $-92.55M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (ALVO)
Nexqual rates ALVO's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 9% |
| Balance Sheet | Mixed — $64M cash vs $1.46B debt |
| Cash Flow | Weak — FCF negative: -$93M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ALVO)
| Insider Ownership | +54.54% |
|---|---|
| Institutional Ownership | +5.11% |
| Shares Outstanding | 338.22M |
| Float | 123.17M |
| Short % of Float | +2.06% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (ALVO)
ALVO is led by Lisa Graver (age 53), Chief Executive Officer, per Nexqual as of July 25, 2026 at 02:21 UTC.
| Chief Executive Officer | Lisa Graver (age 53) |
|---|---|
| Founder & Executive Chairman | Vilhelm Robert Wessman (age 56) |
| Chief Financial Officer | Linda Jonsdottir (age 47) |
| Chief Operating Officer | Joseph E. McClellan (age 51) |
| Vice President of Investor Relations & Global Communications | Benedikt Stefansson |
Major Backers & Investors (ALVO)
Notable institutional backers of ALVO include Bracebridge Capital, LLC, Millennium Management, Price (T.Rowe) Associates Inc, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bracebridge Capital, LLC | 0.87% |
| Millennium Management | 0.68% |
| Price (T.Rowe) Associates Inc | 0.53% |
| Littlejohn & Co LLC | 0.42% |
| T. Rowe Price | 0.36% |
| Global Macro Absolute Return Advantage Portfolio | 0.24% |
| JPMorgan | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.46% |
| BlackRock | 0.72% |
| Legal & General Group PLC | 0.16% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHC | Sotera Health Company | USD 17.35 | ▲ 0.35% |
| GBTG | Global Business Travel Group, I | USD 9.41 | ▲ 0% |
| PROK | ProKidney Corp. | USD 1.5 | ▼ 1.96% |
| EVO | Evotec SE | USD 1.94 | ▼ 0.51% |
| ROIV | Roivant Sciences Ltd. | USD 35.01 | ▲ 0.29% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.